Clinical Trials Logo

Clinical Trial Summary

Kligman's trio remains the gold standard treatment for melasma. It contain hydroquinone which is an effective anti-melanogenic compound but that has poor tolerance and numerous side-effects. Thiamidol has been proven to be at least as effective as hydroquinone and has a very good safety profile. The objective of this study is to compare the Kligman's trio to the same preparation in which hydroquinone is replaced by thiamidol.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05119413
Study type Interventional
Source Centre Hospitalier Universitaire de Nice
Contact Thierry Passeron, phD
Phone +33492036488
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date November 15, 2021
Completion date November 15, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT01976273 - A Pilot Study Testing 1064nm Q-switch Laser Versus Glycolic Acid Peels for the Treatment of Melasma N/A
Terminated NCT00863278 - Treatment of Melasma With Stabilized Kligman Preparation Associated or Not With Pulsed Dye Laser Phase 4
Recruiting NCT00927771 - Azelaic Acid Versus Hydroquinone in Melasma Phase 4
Active, not recruiting NCT01976286 - A Pilot Study Testing Salicylic Acid Peels Versus Glycolic Acid Peels for the Treatment of Melasma N/A
Not yet recruiting NCT03585179 - Oral and Topical Tranexamic Acid for the Treatment of Melasma Phase 3